The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Characterizing aggressiveness and predicting future progression of CF lung disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“preserving lung function is a primary goal of CF clinical care [ 2 , 3 ].”
From EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS (2023) · cites this paper as [2]
In the citing paper
“More rapid decline is associated with more severe CF lung disease and earlier mortality”
From EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS (2023) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis
Konstan, M. W., Butler, S. M., Wohl, M. E. B., Stoddard, M., Matousek, R., Wagener, J. S., Johnson, C. A., & Morgan, W. J. (2003) · The Journal of Pediatrics · doi:10.1067/mpd.2003.152 · Cited by 393
Self-citation
Research works printed but not linked: 15
- Davis, 1996, Cystic fibrosis: state of the art, Am J Respir Crit Care Med, 154, 1229, 10.1164/ajrccm.154.5.8912731 · DOI
- Grosse, 2004, Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs, MMWR Recomm Rep, 53, 1
- Johnson, 2003, Factors influencing outcomes in cystic fibrosis: a center-based analysis, Chest, 123, 20, 10.1378/chest.123.1.20 · DOI
- Corey, 1997, Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis, J Pediatr, 131, 809, 10.1016/S0022-3476(97)70025-8 · DOI · Paper page
- Schluchter, 2002, Jointly modeling the relationship between survival and pulmonary function in cystic fibrosis patients, Stat Med, 21, 1271, 10.1002/sim.1104 · DOI
- Kerem, 1992, Prediction of mortality in patients with cystic fibrosis, N Engl J Med, 326, 1187, 10.1056/NEJM199204303261804 · DOI · Paper page
- Schluchter, 2006, Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data, Am J Respir Crit Care Med, 174, 780, 10.1164/rccm.200512-1919OC · DOI
- Morgan, 1999, Epidemiologic Study of Cystic Fibrosis: design and implementation of a prospective, multicen-ter, observational study of patients with cystic fibrosis in the U.S. and Canada, Pediatr Pulmonol, 28, 231, 10.1002/(SICI)1099-0496(199910)28:4<231::AID-PPUL1>3.0.CO;2-2 · DOI
- Konstan, 2007, Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis, J Pediatr, 151, 134, 10.1016/j.jpeds.2007.03.006 · DOI
- Davis, 1997, Identifying treatments that halt progression of pulmonary disease in cystic fibrosis, Pediatr Res, 41, 161, 10.1203/00006450-199702000-00001 · DOI
- Konstan, 1995, Effect of high-dose ibuprofen in patients with cystic fibrosis, N Engl J Med, 332, 848, 10.1056/NEJM199503303321303 · DOI
- Lands, 2007, High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial, J Pediatr, 151, 249, 10.1016/j.jpeds.2007.04.009 · DOI
- Konstan, 2007, Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis, Am J Respir Crit Care Med, 176, 1084, 10.1164/rccm.200702-181OC · DOI
- Ren, 2008, The initiation of inhaled corticosteroid therapy in cystic fibrosis patients is associated with a slower rate of lung function decline, J Pediatr, 153, 746, 10.1016/j.jpeds.2008.07.010 · DOI
- Konstan, 2006, Pulmozyme® (dornase alfa) use is associated with a slower rate of lung function decline in patients with cystic fibrosis, Pediatr Pulmonol, s337
Cited by
Sorted by citations
Decade-long bacterial community dynamics in cystic fibrosis airways
Zhao, J., Schloss, P. D., Kalikin, L. M., Carmody, L. A., Foster, B. K., Petrosino, J. F., Cavalcoli, J. D., VanDevanter, D. R., Murray, S., Li, J. Z., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120577109 · Cited by 599
Self-citationLee, T., Sawicki, G. S., Altenburg, J., Millar, S. J., Geiger, J. M., Jennings, M. T., Lou, Y., McGarry, L. J., Van Brunt, K., & Linnemann, R. W. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.12.009 · Cited by 56
Metadata
- Authors
- Konstan, M. W., Wagener, J. S., & VanDevanter, D. R.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 8
- Pages
- S15-S19
- ISSN
- 1569-1993
- PMC
- PMC4167362
- Cited by
- 55
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
